- Obesity and overweight - World Health Organization (WHO)
Obesity and overweight fact sheet from WHO providing key facts and information on causes, health consequences, double burden of disease, prevention, WHO response
- Obesity - World Health Organization (WHO)
Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health A body mass index (BMI) over 25 is considered overweight, and over 30 is obese In 2019, an estimated 5 million noncommunicable disease (NCD) deaths were caused by higher-than-optimal BMI
- The challenge of obesity - World Health Organization (WHO)
Obesity, the challenge ofKey facts Overweight and obesity are among the leading causes of disability and death in the WHO European Region; recent estimates suggest that they cause more than 1 2 million deaths across the Region every year Overweight and obesity are the fourth most common risk factor for noncommunicable diseases (NCDs) in the Region, after high blood pressure, dietary risks and
- Obesity - World Health Organization (WHO)
Obesity has reached epidemic proportions globally, with at least 2 8 million people dying each year as a result of being overweight or obese
- Noncommunicable diseases - World Health Organization (WHO)
Noncommunicable diseasesNoncommunicable diseases (NCDs), including heart disease, stroke, cancer, diabetes and chronic lung disease, are collectively responsible for 74% of all deaths worldwide More than three-quarters of all NCD deaths, and 86% of the 17 million people who died prematurely, or before reaching 70 years of age, occur in low- and middle-income countries NCDs share five major
- Obesity: Health consequences of being overweight
Obesity: Health consequences of being overweight 1 March 2024 | Questions and answers What are the health consequences of being overweight? Being overweight or obese can have a serious impact on health
- WHO issues global guideline on the use of GLP-1 medicines in treating . . .
To address the growing global health challenge of obesity, which affects more than 1 billion people, WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease
- Obesity: GLP-1 therapies - World Health Organization (WHO)
GLP-1 therapies (glucagon-like peptide-1 receptor agonists) are a class of medications that mimic the natural GLP-1 hormone, which helps regulate blood sugar and appetite They were originally used for managing type 2 diabetes, but are now also approved for treating obesity and weight loss Some GLP-1 drugs lower the risk of heart attack, stroke, and heart failure, and reduce the incidence of
|